Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 27, Number 3—March 2021

Dispatch

Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection

Pyoeng Gyun Choe1, Kye-Hyung Kim1, Chang Kyung Kang, Hyeon Jeong Suh, EunKyo Kang, Sun Young Lee, Nam Joong Kim, Jongyoun YiComments to Author , Wan Beom ParkComments to Author , and Myoung-don Oh
Author affiliations: Seoul National University College of Medicine, Seoul, South Korea (P.G. Choe, C.K. Kang, H.J. Suh, E. Kang, S.Y. Lee, N.J. Kim, W.B. Park, M.-d. Oh); Pusan National University School of Medicine, Busan, South Korea (K.-H. Kim, J. Yi)

Main Article

Table 2

Positivity of antibodies to severe acute respiratory syndrome coronavirus 2 in 58 asymptomatic or mildly symptomatic patients at 8 mo after infection, South Korea*

Characteristic Anti-N pan-Ig ECLIA, no. (%)† Anti-N IgG ELISA, no. (%)‡ Anti-S IgG ELISA, no. (%)§ Anti-S1 IgG ELISA, no. (%)¶ sVNT, no. (%)#
Total
 53/58 (91.4)
 15/58 (25.9)
 50/58 (86.2)
 40/58 (69.0)
 31/58 (53.4)
Sex
M 21/23 (91.3) 1/23 (4.3) 17/23 (73.9) 11/23 (47.8) 7/23 (30.4)
F
 32/35 (91.4)
 14/35 (40.0)**
 33/35 (94.3)††
 29/35 (82.9)**
 24/35 (68.6)**
Age, y
<30 35/38 (92.1) 5/38 (13.2) 33/38 (86.8) 25/38 (65.8) 19/38 (50.0)
>30
18/20 (90.0)
 10/20 (50.0)**
 17/20 (85.0)
 15/20 (75.0)
 12/20 (60.0)
Duration of PCR positivity
<14 d 3/6 (50.0) 3/6 (50.0) 4/6 (66.7) 3/6 (50.0) 2/6 (33.3)
>14 d
 48/50 (96.0)**
 10/50 (20.0)
 44/50 (88.0)
 36/50 (72.0)
 27/50 (54.0)
Disease severity
Asymptomatic 7/7 (100) 0/7 (0) 5/7 (71.4) 4/7 (57.1) 4/7 (57.1)
Mildly symptomatic 46/51 (90.2) 15/51 (29.4) 45/51 (88.2) 36/51 (70.6) 27/51 (52.9)

*Anti-N, antinucleocapsid; anti-S, antispike; anti-S1, antispike subunit; ECLIA, electrochemiluminescence immunoassay; pan-Ig, panimmunoglobulin; sVNT, surrogate virus neutralization test.
†Roche Diagnostics (https://diagnostics.roche.com). 
‡Epitope Diagnostics (https://www.epitopediagnostics.com).
§InBios International (https://www.inbios.com).
¶Euroimmun (https://www.euroimmune.com).
#GenScript (https://www.genscript.com).
**p<0.01.
††p<0.05.

Main Article

1These first authors equally contributed to this article.

Page created: December 22, 2020
Page updated: February 21, 2021
Page reviewed: February 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external